- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04448444
Brain Activity Changes Following Neuroproprioceptive Physiotherapy in Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study was designed as parallel group randomized comparison of two kinds of physiotherapeutic interventions referred to healthy controls.
MS patients were examined by fMRI (primary outcomes) and clinical tests (secondary outcomes) at the beginning of study. Then, they were randomly divided into two groups (by drawing lots in a 1:1 ratio). The first group underwent Vojta reflex locomotion (VRL), and the second Motor Program Activating Physiotherapy (MPAT). The length and intensity of treatment was the same in both groups (two months, one hour twice a week). After the treatment, a clinical and fMRI examination was performed. Healthy volunteers underwent an fMRI examination that was considered to be a control.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- definite MS
- stable clinical status in the preceding 3 months
- imuno-modulatory treatment for at least two years (including glatiramer acetate, interferon beta-1a, 1b, mitoxantrone, fingolimod, natulizumab)
- Expanded Disability Status Scale (EDSS)≤6
- predominant motor impartment
- six months or more without any physiotherapy
- ability to undergo ambulatory physiotherapy
Exlusion criteria:
-other neurological disease or conditions disabling movement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Motor Program Activating Therapy (MPAT)
The MPAT was chosen for our clinical experience - it was developed and verified by our team.
In this therapy, patients are corrected into a postural position where the joints are functionally centred.
Then somatosensory (manual and verbal) stimuli are applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when the patient is lying, sitting, standing up or moving forward.
Activated programs are repeated under various conditions and in different situations and environments to teach the patients to use the acquired motor skills automatically in daily life.
|
Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration).
Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
|
Experimental: Vojta Reflex Locomotion (VRL)
VRL was developed by prof.
Vojta and is standardly used in the Czech Republic.
In this therapy, patients should be set up into the precisely given initial position with defined angular setting of extremities.
In each position (supine, prone, lying on the side, and low kneeling position), activation points (zones) are stimulated with precise localization and pressure direction.
Such stimulation activates one of the global movement patterns (reflex turning and reflex creeping) corresponding to the initial position.
In addition to motor involuntarily reaction, also sensory and autonomic response is activated.
|
Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration).
Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
|
No Intervention: healthy controls
sex and age matched healthy controls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain activity
Time Frame: 0 month
|
fMRI examinations on 3T magnetic resonance scanner (Siemens Trio Tim, Erlangen, Germany) using a 12-channel head coil (different pattern of brain activity in healthy and people with MS)
|
0 month
|
Brain activity
Time Frame: 0 and 2 months
|
fMRI examinations on 3T magnetic resonance scanner (Siemens Trio Tim, Erlangen, Germany) using a 12-channel head coil (different pattern of brain activity before and after two months of physiotherapeutic program)
|
0 and 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nine Hole Peg Test - NHPT
Time Frame: 2 months
|
measure finger dexterity (quicker time means better function)
|
2 months
|
Paced Auditory Serial Addition Test - PASAT
Time Frame: 2 months
|
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability.
The PASAT is presented using audio record to ensure standardization in the rate of stimulus presentation.
Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it.
The score for the PASAT is the total number correct out of 60 possible answers.
|
2 months
|
Berg Balance Scale - BBS
Time Frame: 2 months
|
14 items objective measure of static balance and risk of falls (0 the best, 56 the worse)
|
2 months
|
Timed 25 Foot Walk - T25FW
Time Frame: 2 months
|
The T25-FW is a quantitative mobility and leg function performance test based on a timed 25-walk.
The patient is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely.
The task is immediately administered again by having the patient walk back the same distance.
The score for the T25-FW is the average of the two completed trials.
|
2 months
|
Timed Up and Go - TUG
Time Frame: 2 months
|
The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance.
It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
|
2 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kamila Řasová, Ph.D., Third Faculty of Medicine Charles University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EK-VP/22/0/2014/2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Motor Program Activating Therapy
-
Charles University, Czech RepublicCompletedMultiple Sclerosis
-
Izmir Katip Celebi UniversityCompleted
-
Ahmed AnwarRecruitingCVA (Cerebrovascular Accident)Egypt
-
Riphah International UniversityCompleted
-
Yusra Medical and Dental CollegeEnrolling by invitation
-
Superior UniversityNot yet recruiting
-
Riphah International UniversityRecruiting
-
Cairo UniversityRecruitingCerebral Palsy, SpasticEgypt
-
Parc de Salut MarRecruiting
-
VA Office of Research and DevelopmentRecruitingChronic StrokeUnited States